DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Adjuvant Tamoxifen
Tamoxifen
Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, hence tamoxifen may be characterized as a mixed agonist/antagonist. It has been the standard endocrine (anti-estrogen) therapy for hormone receptor-positive early breast cancer in pre-menopausal women, although aromatase inhibitors have been proposed. Some breast cancer cells require estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells...
Adjuvant Tamoxifen - List of case studies
- Drugs
-
D Actinomycin-D and ifosfamide) Adenexae Adjuvant Tamoxifen Adjuvant chemotherapy Adjuvant treatment with Interferon ...
- Ovarian Cancer with Metastases
-
Rec. Prog. 90% +. This was followed by adjuvant chemotherapy with carboplatin x 6 cycles from , the last being ... ), Gemetabare , Nomafen (20 mg x1), Tamoxifen, Taxol, Gemetabare, Paxol, Caelyx-Oxaliplatin ( Oxilaplatin, ...
- Infiltrating Duct Carcinoma of Breast
-
therapy. He also recommends to complete the ongoing adjuvant irradiation program, to complete staging procedures, and to undergo ... patient should receive at least a 5 year treatment by Tamoxifen switched to aromatase inhibitor . The particulars of this program ...
- Infiltrating Duct Carcinoma of Breast – additional opinion
-
on these findings the expert advises that she receive adjuvant radiotherapy and hormonotherapy. The adjuvant hormonotherapy consist of initial treatment by Tamoxifen for 2 years, thereafter switched to an Aromatase Inhibitor. The ...